Randomized study of ibrutinib versus ibrutinib plus rituximab (i versus iR) in patients with relapsed chronic lymphocytic leukemia (CLL)
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2017
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms i versus iR
- 21 Aug 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 24 Jun 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology